Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis

Table 1 Clinical features of the two groups classified according to the therapeutic agent

	Group U (n = 48)	Group P (n = 88)	P
Age (yr)	45 (17-74)	51 (15-78)	ns
Sex (female)	45 (93.8%)	65 (73.9%)	< 0.01
Acute presentation	5 (10.4%)	31 (36.5%)	< 0.01
Laboratory data
AST (IU/L)	104 (46-1234)	303 (31-2215)	< 0.001
ALT (IU/L)	149 (52-1000)	431 (38-2801)	< 0.001
T.Bil (mg/dL)	0.8 (0.3-18)	1.3 (0.4-19.3)	< 0.05
ALP (U/L)	300 (144-1184)	369 (145-4420)	ns
γ-GTP (U/L)	82 (13-875)	183 (12-1256)	< 0.05
IgG (mg/dL)	1954 (1096-3793)	2336 (1051-5776)	< 0.01
ANA (≥ 1 : 40)	46 (95.8%)	83 (94.3%)	ns
SMA (≥ 1 : 40)	11/23 (47.8%)	35/45 (77.8%)	< 0.05
HLA DR4	6/16 (37.5%)	33/57 (57.9%)	ns
Histological finding
Grading
A1	29 (60.4%)	25 (28.4%)	< 0.01
A2	18 (37.5%)	44 (50%)
A3	1 (2.1%)	19 (21.6%)
Staging
F1	35 (72.9%)	43 (48.9%)	< 0.05
F2	6 (12.5%)	28 (31.8%)
F3	6 (12.5%)	10 (11.4%)
F4	1 (2.1%)	7 (8.0%)
AIH score
Revised score	15 (10-20)	16 (7-23)	ns
Simplified score	6 (4-8)	6 (3-8)	ns

Continuous variables are expressed as median (range) values. The Mann-Whitney U test was used to evaluate differences in continuous variables between two groups. Dichotomous variables were compared by Pearson’s χ² test. Values of P < 0.05 were considered significant. ALT: Alanine aminotransferase; AIH: Autoimmune hepatitis; AST: Aspartate transaminase; HLA: Human leukocyte antigen; ANA: Antinuclear antibody; ALP: Alkaline phosphatase; γ-GTP: γ-glutamyltransferase; SMA: Smooth muscle antibody; ns: No significant difference; T.Bil: Total bilirubin; IgG: Immunoglobulin G.